Skip to main navigation Skip to search Skip to main content

Sensorineural hearing loss after concurrent chemoradiotherapy in nasopharyngeal cancer patients

  • Faculty of Medicine Siriraj Hospital, Mahidol University
  • Ubon Ratchathani Cancer Center

Research output: Contribution to journalArticlepeer-review

60 Citations (Scopus)

Abstract

Background: Sensorineural hearing loss (SNHL) is one of the major long term side effects from radiation therapy (RT) in nasopharyngeal cancer (NPC) patients. This study aims to review the incidences of SNHL when treating with different radiation techniques. The additional objective is to determine the relationship of the SNHL with the radiation doses delivered to the inner ear.Methods: A retrospective cohort study of 134 individual ears from 68 NPC patients, treated with conventional RT and IMRT in combination with chemotherapy from 2004-2008 was performed. Dosimetric data of the cochlea were analyzed. Significant SNHL was defined as > 15 dB increase in bone conduction threshold at 4 kHz and PTA (pure tone average of 0.5, 1, 2 kHz). Relative risk (RR) was used to determine the associated factors with the hearing threshold changes at 4 kHz and PTA.Results: Median audiological follow up time was 14 months. The incidence of high frequency (4 kHz) SNHL was 44% for the whole group (48.75% in the conventional RT, 37% with IMRT). Internal auditory canal mean dose of > 50 Gy had shown a trend to increase the risk of high frequency SNHL (RR 2.02 with 95% CI 1.01-4.03, p = 0.047).Conclusion: IMRT and radiation dose limitation to the inner ear appeared to decrease SNHL.

Original languageEnglish
Article number19
JournalRadiation Oncology
Volume6
Issue number1
DOIs
Publication statusPublished - 20 Feb 2011

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Sensorineural hearing loss after concurrent chemoradiotherapy in nasopharyngeal cancer patients'. Together they form a unique fingerprint.

Cite this